Rexahn Pharmaceuticals Email Format

Pharmaceutical ManufacturingMaryland, United States2-10 Employees

Rexahn Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its approach centers on compounds designed to block specific proteins involved in cancer cell growth, with the aim of achieving strong efficacy while reducing the toxicity associated with traditional treatments. Preclinical studies suggest potential across multiple cancer types, including drug-resistant and difficult-to-treat cancers, and some candidates may enhance the effectiveness of existing FDA-approved therapies. The company is based in Rockville, Maryland, and operates with a small team, trading on the NYSE American market.

Rexahn currently has two oncology candidates, RX-3117 and RX-5902, in Phase 2 development, with additional compounds in preclinical stages such as RX-0201. In February 2020, the company signed a license agreement with Zhejiang HaiChang Biotechnology Co., Ltd. to develop and commercialize RX-0201 (the nano-liposomal formulation RX-0301) for hepatocellular carcinoma, and RX-0047, a hypoxia-inducible factor-1 alpha inhibitor that is in preclinical development.

Get verified Rexahn Pharmaceuticals emails free

Company overview Employee directory